source
- Sanofi pays Regeneron $1B upfront to continue search for Dupixent successorSanofi and Regeneron have had a long and “sometimes contentious” partnership, BMO Capital Markets noted, as the companies contend with the looming loss of exclusivity of their blockbuster drug Dupi…BioSpace · 20d ago↗ source
- Lilly’s EloraTZP combo shows superior weight loss and glucose control, moves to Phase 3Eli Lilly reported that its experimental combination, EloraTZP, which pairs an amylin agonist with the approved obesity drug Zepbound, met all primary and secondary goals in a mid‑stage study of ad…